Geron Co. (NASDAQ:GERN)’s share price traded up 3.3% during mid-day trading on Wednesday . The company traded as high as $4.22 and last traded at $3.86. 2,153,179 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 6,281,719 shares. The stock had previously closed at $3.99.
A number of equities analysts have issued reports on the company. BidaskClub downgraded Geron from a “strong-buy” rating to a “buy” rating in a report on Friday, March 30th. Piper Jaffray reiterated a “buy” rating and issued a $7.00 price objective on shares of Geron in a report on Monday, March 19th. Zacks Investment Research upgraded Geron from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Wednesday. Stifel Nicolaus raised their price target on Geron from $2.50 to $4.00 and gave the company a “hold” rating in a report on Sunday, March 18th. Finally, ValuEngine upgraded Geron from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Geron currently has an average rating of “Buy” and an average price target of $5.17.
The firm has a market cap of $608.88, a price-to-earnings ratio of -21.23 and a beta of 2.29.
Geron (NASDAQ:GERN) last issued its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Geron had a negative net margin of 2,621.22% and a negative return on equity of 25.25%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.41 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. Geron’s revenue was up 103.2% compared to the same quarter last year. equities research analysts predict that Geron Co. will post 0.01 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Geron by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 1,344,758 shares of the biopharmaceutical company’s stock valued at $2,420,000 after acquiring an additional 25,058 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in Geron in the 4th quarter worth about $136,000. Millennium Management LLC increased its holdings in Geron by 573.5% in the 4th quarter. Millennium Management LLC now owns 101,800 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 86,684 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Geron by 97.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 238,143 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 117,457 shares in the last quarter. Finally, Creative Planning increased its holdings in Geron by 69.8% in the 4th quarter. Creative Planning now owns 308,523 shares of the biopharmaceutical company’s stock worth $555,000 after buying an additional 126,810 shares in the last quarter. Hedge funds and other institutional investors own 36.89% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Geron (GERN) Trading -3.3% Higher” was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/04/18/geron-gern-trading-3-3-higher.html.
Geron Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.